No. | Sex | Age | Site | Stage | RT | Chemotherapy | Local response | Site of failure | TTP (months) | Survival (months) | |
---|---|---|---|---|---|---|---|---|---|---|---|
Dose (Gy/Fxs) | CCRT | After CCRT | |||||||||
1 | M | 42 | Head | T4N1 | 50/20 | 5-FU | GEM | SD | Distant | 7.6 | 12.1* |
2 | M | 64 | Head | T4N0 | 50/20 | 5-FU | GEM | PR | 7.6* | ||
3 | M | 72 | RM | Recurrent† | 50/20 | 5-FU | GEM | SD | Distant | 7.9 | 26.0* |
4 | F | 61 | Head | T4N0 | 50/20 | 5-FU | GEM | PR | 7.2* | ||
5 | M | 74 | Body | T4N0 | 50/20 | 5-FU | GEM | SD | Distant | 2.0 | 9.8* |
6 | M | 63 | Tail | T4N0 | 50/20 | 5-FU | GEM | PR | Distant | 6.0 | 9.2* |
7 | F | 61 | Celiac trunk | Recurrent† | 50/20 | 5-FU | 5-FU/LV | PR | Distant | 8.0 | 12.8* |
8 | M | 66 | Body | T4N1 | 50/20 | 5-FU | SD | Local/Distant | 14.6 | 22.7* | |
9 | M | 71 | Body | T4N0 | 50/20 | 5-FU | GEM | PR | Distant | 13.9 | 19.4* |
10 | M | 68 | Head | T4N0 | 45/15 | 5-FU | GEM | PR | Distant | 8.0 | 20.0* |
11 | F | 56 | Celiac trunk | Recurrent† | 45/15 | 5-FU | GEM | PR | Distant | 4.9 | 6.9 |
12 | F | 66 | Head | T4N1 | 45/15 | 5-FU | GEM | SD | 5.7 |